Research programme: Pim kinase inhibitors - Selvita

Drug Profile

Research programme: Pim kinase inhibitors - Selvita

Alternative Names: SEL24; SEL24 program; SEL24-1; SEL24-B489

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Selvita
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Lymphoma

Most Recent Events

  • 10 Dec 2016 Preclinical trials in Acute myeloid leukaemia in USA (PO) before December 2016
  • 10 Dec 2016 Selvita plans a phase I/II trial for Acute myeloid leukaemia in USA (NCT03008187)
  • 18 Apr 2016 Selvita files an IND application with the US FDA in USA for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top